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Background: Electrochemical skin conductance measurement is an active electrophysiologic method in which incremental low direct voltage is
applied on the skin. It generates a current due to reverse iontophoresis which previous studies suggested to be mostly related to chloride anion
movements. As sweat chloride movements upon electric stimulation were likely to be impaired in cystic fibrosis (CF) patients, we designed a
proof-of-concept study to measure electrochemical skin conductance in CF patients and control subjects and to test the ability of this method to
discriminate CF from controls.
Methods: Electrochemical skin conductance was measured in 41 adult patients with classical CF and 20 healthy control subjects. Patients placed
their hands and feet on nickel electrodes and an incremental low direct voltage was applied on the anode during 2 min. The resulting voltage on
the cathode and the current generated between anode and cathode were measured and from them, two electrochemical skin conductance variables
were calculated: ESC, obtained when a low voltage of 1.6 V was applied, and dESC which took into account electrochemical skin conductances
obtained when low and high voltages were applied.
Results: ESC measurements on hands and feet were significantly different in CF patients (on feet: 75±10 μSi), as compared with control subjects
(62±13 μSi, pb0.0001); dESC was also significantly different and more discriminative in CF patients (on feet: 34±24 μSi), as compared with
control subjects (93±24 μSi, pb0.0001). dESC measurement provided a diagnostic specificity of 1 and a sensitivity of 0.93.
Conclusions: These results show that electrochemical skin conductance which is easily and rapidly measured is abnormal in CF patients.
Trial registry name in the European Clinical Trials Database (eudraCT): “EZSCAN MUCO1: Mesure de la conductance cutanée par
chronoampérométrie”, N°EUDRACT: 2007-A00221-52.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Sweat test; Electrochemical conductance1. Introduction
Cystic fibrosis (CF) is the most frequent lethal autosomal
recessive disorder in Caucasians [1]. It is characterized by
defective electrolyte transport across secreting epithelia [2,3]. It is☆ This work has been presented at the European Cystic Fibrosis Conference,
in France, in June 2009.
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doi:10.1016/j.jcf.2010.09.002due to mutations in the Cystic Fibrosis Conductance Transmem-
brane Regulator (CFTR) gene which encodes a chloride channel
that also regulates other ion channels [4,5]. CF diagnosis is based
on the presence of one or more characteristic phenotypic features
and laboratory evidence showing elevated sweat chloride
concentration [6,7]. There are several critical issues associated
with sweat testing that can challenge the evaluation of a sweat test
result. A reliable sweat test depends on the use of appropriate
methods, as described in various guidelines, performed by
documented competent laboratories with active quality control
and quality assurance programs [8–10]. New technologies withd by Elsevier B.V. All rights reserved.
Fig. 1. General presentation of the device measuring electrochemical skin
conductance. Hand and feet nickel electrodes and electronic board allowing
voltage application, current and voltage measurements, recordings and data
management.
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be of great interest to evaluate CF or CFTR-related disease
likelihood [11]. Moreover, with the growing pipeline of candidate
drugs for CF, the development of new real-timemarkers assessing
CFTR function is needed [12].
The defect in the CFTR chloride channel results in an altered
bioelectrical potential in the CF sweat gland [13]. This is the basis
of a new assay recently described by Gonska et al. in which the
sweat gland potential difference was measured and discriminated
CF from control subjects [14]. The sweat duct can also be
explored by using active electrophysiology, such as measurement
of electrochemical skin conductance after application of an
incremental low direct voltage. This low voltage applied on
human skin generates a current through reverse iontophoresis, i.e.
ion movements via sweat duct pores in response to electric
stimulation. In vitro studies performed with sweat mimicking
solutions suggested that movements of chloride played an
important role in these electrochemical reactions [15]. As sweat
chloride movements upon electric stimulation were likely to be
impaired in CF patients, we designed a proof-of-concept study in
order to measure electrochemical skin conductance in CF patients
and control subjects and to test the ability of this method to
discriminate CF from controls. Some of the results of this study
have been previously reported in the form of an abstract [16].
2. Methods
2.1. Study subjects
The study included 41CF patients (mean age±SD: 28±9 years;
25 men) and 20 control subjects (mean age±SD: 25±10 years;
10 men). CF patients had a typical disease with characteristic
clinical manifestations, abnormal sweat chloride concentrations
(mean±SD: 95±15 mmol/L, as determined by colorimetry in
accordance with the guidelines [10]) and the presence of 2
CFTR mutations, except for 2 patients: CFTR genotyping was
not done in one patient and for the other, only one mutation
(1811+1.6ANG)was found. Their sweat chloride concentrations
were 121 and 99 mmol/L, respectively. For the other patients,
CFTR mutations were the following: 17 patients were homozy-
gous for the F508del mutation, 16 patients were heterozygous for
F508delmutation and the othermutationwas:W1282X,X1481W,
S945L, R347H, M1101K, I507del, E92K, 3849+10kbCNT,
3121-1GNA, 2894insANG, 1924del7, I148T-3199del6, R553X
for 2 patients and 3272-26ANG for 2 patients. The 6 remaining
patients had the following CFTR genotypes: G542X/L206W,
Y122X/L206W, Y122X/Y122X, G551D/S492F, R792X/R334W
and 167del TNA/V754M. Control subjects were normal indivi-
duals without any respiratory symptoms, with no relative with CF
and with normal sweat chloride concentrations (19±7 mmol/L).
The study was approved by the ethical committee of our hospital
and all subjects signed informed consent.
2.2. Electrochemical skin conductance measurements
The patient placed his hands and feet on two sets of large
area nickel electrodes connected to an electronic board managedby a computer for recordings and data management (Fig. 1). He
was asked to stand up without moving his hands and feet during
the 2 min that required the measurement. The sites of the
electrodes have been chosen because of their high density of
sweat glands. For one measurement configuration (for instance
right hand–left hand), the right hand electrode was used as an
anode and a voltage of 1 V was applied during 1 s. This induced
a voltage on the cathode, i.e. the left hand electrode, and a
current going through the body towards the cathode. The
voltage occurring on the cathode was measured by using a
voltmeter and the current between both electrodes was mea-
sured by using a Wheatstone bridge (Impeto Medical®, Paris,
17D. Hubert et al. / Journal of Cystic Fibrosis 10 (2011) 15–20France). Then, the voltage applied on the anode was increased
up to 1.2 V during 1 s and a new measurement was performed.
Such a progressive step by a step increase of 0.2 V during 1 s
was applied until a maximal voltage of 3.8 V was reached (15
steps in all). Then, the same 15 steps of incremental voltage
were applied on the left hand electrode used as anode while the
right hand electrode was used as cathode. Finally, the same 15
steps were applied twice on the feet electrodes, with each
electrode used alternatively as an anode or a cathode.
The current measured at each voltage was plotted against the
difference between the voltage applied on the anode and the
voltage measured on the cathode (Δanode−cathode) (Fig. 2).
As shown in Fig. 2, the curve obtained was linear when voltages
applied, and thus the resulting (Δanode−cathode) difference,
were low. Electrochemical skin conductance is the slope of this
curve, i.e. the ratio between the current measured and the
difference obtained (Δanode−cathode). We defined ESC as the
electrochemical skin conductance when a voltage of 1.6 V was
applied on the anode (4th step in the 15 steps of voltage
applied). This value was chosen because it was the most
discriminant one at low voltages. As shown in Fig. 1, with
increasing voltages applied and mostly for control subjects, the
curve no longer followed the line obtained at low voltages and
this was expressed as the difference between electrochemical
skin conductances (dESC): the difference between electro-
chemical skin conductance calculated at 3.6 V (i.e. the ratio
between the current measured and (Δanode−cathode) obtained
when a voltage of 3.6 V was applied on the anode) and ESC
(obtained at 1.6 V). The voltage step 3.6 V was chosen because
it was one of the highest voltages applied and the mostFig. 2. Individual current density–voltage curves for a control subject (Ct, black
squares) and a patient with cystic fibrosis (CF, black circles). Electrochemical
skin conductance is the slope of the curve, i.e. the ratio between the current
measured (Y-axis) and the difference in voltages obtained (Δanode−cathode:
X-axis). ESC is the electrochemical skin conductance when a voltage of 1.6 V
was applied on the anode (i.e. the slope of the curve obtained at the 4th step of
increasing voltage, corresponding to the 4th point of each curve). dESC is the
difference between the electrochemical skin conductance obtained at 3.6 V (i.e.
the slope obtained when a voltage of 3.6 V was applied on the anode, which was
the 14th step of increasing voltage corresponding to the 14th point of each
curve) and ESC (obtained at 1.6 V). dESC is shown on the figure by the up
down arrow.discriminant between CF patients and control subjects. Both
ESC and dESC were expressed in μSiemens (μSi). The data
were displayed instantaneously in the form of a geometric figure
that allowed fast, intuitive interpretation. Detailed results were
provided in alphanumerical form.
2.3. Statistical analysis
Results were expressed as mean±SD. Means of each group
were compared by a two sided Student's t-test. A p-valueb0.05
was regarded as statistically significant. The repeatability was
studied by the Bland–Altman method [17] and the results
expressed as mean [95% confidence interval]. The precision of
the method, i.e. the mean of absolute values of difference
between the two measurements performed for a subject divided
by the average of the means of all measurements, was
calculated. The diagnostic performance of electrochemical
skin conductance measurement was analyzed by a receiver–
operator characteristic (ROC) curve, allowing to determine the
sensitivity, specificity and the accuracy of the diagnostic test by
the area under the ROC curve (AUC). A value of 0.5 under the
ROC curve indicates that the variable performs no better than
chance, a valueN0.7 is considered “fair”, N0.8 as “good”, N0.9
as “excellent” and 1.0 indicates perfect discrimination.
3. Results
3.1. Electrochemical skin conductance measurements
There was a broad range of results for hands and feet
ESC in both CF patients and control subjects (Fig. 3). However,
ESC on the hands were significantly different in CF patients
(73±14 μSi), as compared with control subjects (61±15 μSi,
pb0.01) (Fig. 3A). ESC measurements on the feet were also
significantly different in CF patients (75±10 μSi), as com-
pared with control subjects (62±13 μSi, pb0.0001) (Fig. 3B).
However, for both hands and feet ESC, there was some overlap
between the two groups.
Although there was a broad range of results in hands and feet
dESC measurements in both CF patients and control subjects,
there was little overlap between the 2 groups (Fig. 4). dESCFig. 3. Electrochemical skin conductance measurements (ESC) when a voltage
of 1.6 V is applied on the anode for hands (A) and feet (B) in control subjects
and patients with cystic fibrosis (CF). (The line for each group is the mean value;
**: pb0.01; ****: pb0.0001).
Fig. 4. dESC on hands (A) and feet (B) in control subjects and patients with
cystic fibrosis (CF). dESC is the difference between the electrochemical skin
conductance obtained at 3.6 V (i.e. the ratio between the current measured and
(Δanode−cathode) obtained when a voltage of 3.6 V was applied on the anode)
and ESC (obtained at 1.6 V). (The dotted line represents the cut-off of 60 μSi;
the line for each group is the mean value; ****: pb0.0001).
Fig. 5. Relation between sweat chloride concentrations and dESC for hands
(A) and feet (B) in control subjects (squares) and patients with cystic fibrosis
(diamonds).
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CF patients (9±18 μSi), as compared with control subjects
(49±31 μSi, pb0.0001). dESC measurements on the feet were
also significantly different in CF patients (34±24 μSi), as com-
pared with control subjects (93±24 μSi, pb0.0001) (Fig. 4B).
For feet dESC measurement and with a cut-off valueb60 μSi
predicting CF, all control subjects had a normal result and only
3 CF patients had feet dESC above the cut-off value (65, 85 and
72 μSi). However, their hands dESC were all in the CF range
(−12, 9 and 0 μSi, respectively). No explanation for this
discrepancy was found in the phenotypes, genotypes or treat-
ments of these 3 patients: they all had pancreatic insufficiency;
their forced expiratory volume in 1 s (FEV1) were: 88, 64 and
32% of predicted value, respectively; their sweat chloride
values were 110, 103 and 67 mmol/L, respectively; their CFTR
genotypes were R792X/R334W, F508del/F508del, F508del/
3849+10kbCNT, respectively.
To study repeatability, a second set of measurements was
performed and analyzed by the Bland–Altman method [17]: the
mean differences [95% CI] between the 2 measurements were:
for hands ESC: 1.78 [0.44; 3.10] μSi, for feet ESC: −1.93
[−2.73; −1.14] μSi, for hands dESC: 3.30 [−4.10; 10.70] μSi,
and for feet dESC: 1.72 [−3.25; 6.70] μSi. Thus, the precision
of the measurements was very good: 0.06 for hands ESC, 0.04
for feet ESC, 0.09 for hands dESC and 0.03 for feet dESC.
3.2. Diagnostic accuracy of dESC measurements, comparison
with sweat chloride concentrations
As feet dESC was the most discriminative measurement, its
diagnostic performance was analyzed by ROC curve modelisa-
tion. With a cut-offb60 μSi predicting CF, dESC measurement
provided a diagnostic specificity of 1, a sensitivity of 0.93 and a
diagnostic performance as assessed by the area under a ROC
curve of 0.96 [95% CI 0.92; 1.00]. dESC and sweat chloride
concentrations were plotted in relation to each other. There was a
good correlation of dESC to sweat chloride, both for hands
(Fig. 5A): the coefficient of correlationwas−0.57 (pb0.0001) and
for feet (Fig. 5B): coefficient of correlation: −0.70 (pb0.0001).3.3. Adverse events
No adverse event was reported during or after the study.
More specifically, no patient perceived the voltage applied or
the current produced. No reddening of the palms of hands or
feet was observed.
4. Discussion
This proof-of-concept study shows that electrochemical skin
conductance which can be measured easily and rapidly is
abnormal in CF patients.
Electrochemical skin conductance measurement which we
here describe is an active electrophysiologic method in which a
low voltage is applied on an anode to generate a current between
anode and cathode that is measured, and a voltage on the
cathode that is also measured. The current is due to reverse
iontophoresis, i.e. movement of ions in response to electric
stimulation and local electrochemical reactions between those
ions and nickel electrodes. On human skin, at the voltages we
applied, ions cannot go through the stratum corneum because of
the very high electrical capacity of its dense lipid layers [18].
Thus, the only way for ions in human skin to move in such an
electric field is via sweat duct pores. From in vitro electro-
chemical studies evaluating Ni electrode behavior upon sweat
mimicking solutions, the concentration of chloride in the solu-
tion had a strong influence on the anodic potential and
suggested electrochemical reactions between chloride anions
and the nickel of the electrodes [15]. The abnormal electro-
chemical skin conductance we found in CF patients supports
these in vitro data pointing to an important role of chloride in
local electrochemical reactions occurring upon electric stimu-
lation. Indeed, the major difference between CF skin and
normal skin is the abnormal chloride absorption in the CF sweat
duct due to the defective CFTR channel [13,19].
Our results show a higher electrochemical skin conductance
in CF as compared with control subjects when low voltages
(1.6 V) are applied. We hypothesize that at low voltages, high
sweat chloride concentration in CF patients allow a larger
electrochemical reaction with Ni, as compared with controls
with low sweat chloride concentrations. This large chloride and
Ni reaction would allow high current and cathodic voltage and
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higher voltages (3.6 V) were applied, results were very different
in CF patients and control subjects: while there was an increase
in electrochemical skin conductance in control subjects, no such
behavior was observed in CF patients. With higher voltages
applied, the sweat gland physiology is likely to be overcome:
although quite low (3.6 V), this voltage is much higher than the
physiological one (in the mV range) and the ion channels in the
sweat duct would consequently function towards ion efflux.
While a large efflux is possible in controls, it is limited in CF
patients for whom sweat chloride is already at baseline in the
maximal physiological range and for whom CFTR chloride
channels in the sweat duct epithelium are poorly expressed/
functional. This would explain why at high voltages, there is no
increase in electrochemical skin conductance in CF patients, as
compared with control subjects. Thus, the calculated dESC that
takes into account electrochemical skin conductances obtained
at low and high voltage appears to be very discriminative for CF
diagnosis.
Although there was a good correlation between sweat
chloride concentration and electrochemical skin conductance,
sweat chloride concentrations cannot be extrapolated from ESC
at present. Further studies are needed to clarify the role of other
sweat ion movements during electrochemical skin conductance
measurements in CF and control subjects. These studies might
allow in the future to extrapolate sweat chloride concentrations
from electrochemical skin conductance measurements. It should
be underlined that electrochemical skin conductance measure-
ment is completely different from sweat conductivity which is
not considered appropriate for CF diagnosis. In contrast with the
method we here describe, sweat conductivity requires a sweat
sample in which concentrations of all ions, including anions
other than chloride, are equally measured [10].
Our present study shows that electrochemical skin conduc-
tancemeasurement is a new test which is abnormal in CF patients.
The present study is a proof-of-concept study. It needs to be
expanded to a larger group of CF patients with broader
phenotypes. It also needs to be assessed in children. Moreover,
the precise ion movements occurring ex vivo and in vivo upon
electric stimulation in the presence of a normal or abnormal CFTR
protein in the sweat duct need to be studied to allow modelling.
However, our study performed in a group of CF adults, suggests
that electrochemical skin conductance measurement could be
used as a CF-diagnostic tool. The test is completely automatic and
results are immediately displayed. It requires no special skill or
training for its operator. It could be performed by the practitioner
during an outpatient consultation, just as blood pressure
measurement or pulmonary function tests. It needs no patient
preparation, it is painless and has no contra-indication. It only
requires that the patient stands quietly during the 2 min-
measurement with hands and feet placed on electrodes. If one
takes into account the time for explanations, setting up the patient
and registration of patient demography, the whole exam is
performed in 10 min. It is noteworthy that the maximal voltage
applied (3.6 V) is quite low (in the range of a usual battery) and
the intensity of the current produced (0.2 mA) is much lower than
the current intensity usually used when iontophoresing the potentsweat secretagogue pilocarpine on an electrically stimulated area
of the skin (around 2 mA). The electrodes and the duration of
measurement could be adapted for children or even infants.
In conclusion, we describe electrochemical skin conductance
measurement and show that it is abnormal in CF adults. This
first proof-of-concept study supports further developments to
assess the diagnostic value of electrochemical skin conductance
measurement in a larger CF population, including children and
infants. In the future, it could be of interest if this quick,
automatic and non invasive measurement could be developed as
a screening test to be confirmed by a sweat test in the case of an
abnormal result. The evaluation of its value as an outcome
measure for CF drug development is also of interest.
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